We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Perfusion Regulators Increase Circulation During Emergencies

By HospiMedica International staff writers
Posted on 27 Aug 2013
Two noninvasive perfusion on demand (POD) devices can help first responders restore patients to full function following medical emergencies. More...


The ResQPOD and ResQGARD impedance threshold devices (ITDs) deliver POD therapy to increase circulation, protecting the heart, brain, and other vital organs when blood flow is compromised. The ResQPOD works by regulating pressures in the thorax during states of hypotension by preventing unnecessary air from entering the chest during cardiopulmonary resuscitation (CPR). As the chest wall recoils, the vacuum in the thorax is greater; this enhanced vacuum pulls more blood back to the heart, doubling blood flow and systolic blood pressure (BP). This increases cardiac output and blood flow to the brain by 50%, without restricting patient ventilation and exhalation.

The ResQGARD increases BP during hypotension from a variety of causes, such as orthostatic intolerance, hypovolemia, heat shock, dialysis, and blood donation. During inspiration, a negative pressure created from expansion of the thorax draws air into the lungs. When inspiratory impedance is applied to the breathing circuit, it enhances the vacuum in the chest, which pulls more blood back to the heart, resulting in increased preload, thus enhancing cardiac output on the subsequent cardiac contraction. The core component of the device is an atmospheric pressure sensing valve that creates the correct amount of therapeutic resistance during inspiration.

In principle, the ResQGARD uses similar technology as the ResQPOD, but is designed for patients who are breathing spontaneously. This is reflected in the valve mechanism itself, the valve cracking pressure, and a supplemental O2 port in the ResQGARD. The ResQPOD and ResQGARD are products of Advanced Circulatory (Roseville, MN, USA), and can be used on a facemask or with a mouthpiece.

“Our Perfusion on Demand therapy has the potential to have a global impact on patient care, and this financing round will help us push education and adoption of our life-saving therapies,” said Mike Black, CEO of Advanced Circulatory.

Related Links:
Advanced Circulatory


Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Resorbable Bovine Collagen Membrane
GenDerm
New
POC Respiratory/Sore Throat Test
BIOFIRE SPOTFIRE (R/ST) Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The new Cora Torqueable Microcatheters expand our coronary portfolio supporting patients with coronary artery disease (photo courtesy of Reflow Medical)

Torqueable Microcatheters Enhance Navigation in Complex Coronary Lesions

Interventional cardiologists frequently encounter tortuous vessels and heavily calcified or fibrotic coronary lesions that complicate guidewire control and device delivery. Stable, predictable torque and... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.